#1 Clinical Trials Search in Europe

Glenzocimab

Glenzocimab is an innovative drug currently being studied in clinical trials for the treatment of acute ischemic stroke. This article explores the ongoing research into glenzocimab’s potential to improve outcomes for stroke patients when used alongside standard treatments like thrombolysis and thrombectomy. We’ll examine the drug’s mechanism of action, its safety profile, and the latest results from clinical studies investigating its efficacy.

Table of Contents

What is Glenzocimab?

Glenzocimab, also known as ACT017, is a new medication being developed to treat acute ischemic stroke and other conditions[1]. It is a type of drug called a monoclonal antibody, which means it’s a laboratory-made protein designed to target specific cells or proteins in the body[2].

How Does Glenzocimab Work?

Glenzocimab works by targeting a specific protein on the surface of blood platelets called glycoprotein VI (GPVI). GPVI plays a crucial role in activating platelets and forming blood clots. By blocking GPVI, glenzocimab aims to prevent excessive blood clotting without significantly increasing the risk of bleeding[1].

In the context of stroke, glenzocimab is designed to:

  • Reduce downstream microvascular thrombosis (DMT), which is the formation of small blood clots in tiny blood vessels
  • Decrease the growth of the ischemic lesion (area of brain damage due to lack of blood flow)
  • Lower the risk of hemorrhagic transformation (bleeding into the damaged brain tissue)
  • Reduce vasogenic edema (swelling in the brain due to leaky blood vessels)

What Conditions Does Glenzocimab Treat?

Glenzocimab is primarily being studied for the treatment of:

  • Acute Ischemic Stroke: This is the most common type of stroke, caused by a blood clot blocking blood flow to part of the brain[1][2][4]
  • SARS-CoV-2 related Acute Respiratory Distress Syndrome (ARDS): A severe lung condition that can occur in COVID-19 patients[3]

Current Clinical Trials

Several clinical trials are currently underway to evaluate the effectiveness and safety of glenzocimab:

  • ACTISAVE: A large, international study testing glenzocimab in acute ischemic stroke patients who have received standard treatments like thrombolysis (clot-busting drugs) and/or thrombectomy (mechanical clot removal)[4]
  • GREEN Study: Evaluating glenzocimab in stroke patients undergoing endovascular therapy (a procedure to remove blood clots from brain arteries)[2]
  • A study for patients with acute ischemic stroke and large ischemic core (extensive brain damage)[1]
  • A trial for COVID-19 patients with ARDS[3]

How is Glenzocimab Administered?

Glenzocimab is given as an intravenous (IV) infusion. In most trials, the typical dose is 1000 mg, administered over 6 hours. The infusion usually starts with a 15-minute bolus (rapid injection) of 1/4 of the dose, followed by a slower infusion of the remaining 3/4 over 5 hours and 45 minutes[1][2][4].

Potential Benefits of Glenzocimab

Early studies suggest that glenzocimab may offer several benefits:

  • Improved functional outcomes after stroke
  • Reduced risk of symptomatic intracranial hemorrhage (bleeding in the brain)
  • Lower mortality rates, especially in severe stroke patients
  • Potential to enhance the effectiveness of current stroke treatments
However, it’s important to note that these potential benefits are still being investigated in ongoing clinical trials[1][2][4].

Safety Profile

Initial studies suggest that glenzocimab may have a favorable safety profile:

  • It appears to have a minimal risk of causing excessive bleeding
  • People with a deficiency in the GPVI protein (which glenzocimab targets) do not typically have an increased risk of bleeding
  • Early trials have shown promising safety data, including reduced rates of symptomatic brain hemorrhage compared to placebo
However, as with all new medications, the full safety profile of glenzocimab will become clearer as more clinical trial data becomes available[1][4].

Aspect Details
Drug Name Glenzocimab (ACT017)
Drug Type Monoclonal antibody targeting platelet glycoprotein VI (GPVI)
Primary Use Treatment of acute ischemic stroke
Administration Intravenous infusion, typically 1000 mg over 6 hours
Mechanism of Action Inhibits platelet activation and aggregation, potentially reducing downstream microvascular thrombosis
Current Research Stage Phase II/III clinical trials
Potential Benefits May improve functional outcomes, reduce ischemic lesion growth, and decrease risk of hemorrhagic transformation
Safety Profile Promising early results with potentially lower bleeding risk compared to other antiplatelet drugs
Use in Treatment Studied as an add-on therapy to standard treatments (thrombolysis and/or thrombectomy)

FAQ

  • What is glenzocimab? Glenzocimab is a monoclonal antibody that targets platelet glycoprotein VI (GPVI), a key receptor involved in platelet activation and blood clot formation. It is being developed as a potential treatment for acute ischemic stroke.
  • How is glenzocimab administered in clinical trials? In clinical trials, glenzocimab is typically administered intravenously. The dosage being studied is often 1000 mg, given over 6 hours, with an initial 15-minute bolus followed by a slower infusion over the remaining time.
  • What is the potential benefit of using glenzocimab in stroke treatment? Glenzocimab may help improve outcomes for stroke patients by reducing downstream microvascular thrombosis, potentially decreasing ischemic lesion growth and the risk of hemorrhagic transformation. It is being studied as an add-on therapy to standard treatments like thrombolysis and thrombectomy.
  • Are there any safety concerns with glenzocimab? Early clinical studies have shown promising safety data for glenzocimab. Unlike some other antiplatelet drugs, it does not appear to significantly increase the risk of bleeding. However, as with all new medications, its safety profile is still being thoroughly evaluated in ongoing clinical trials.
  • What is the current stage of research for glenzocimab? Glenzocimab is currently being studied in multiple phase II and phase III clinical trials for acute ischemic stroke. These studies are evaluating its efficacy and safety when used alongside standard stroke treatments, with results expected to provide more information on its potential benefits and risks.

Ongoing Clinical Trials on Glenzocimab

  • Study on Glenzocimab for Patients with Acute Ischemic Stroke Undergoing Mechanical Thrombectomy

    Not recruiting

    4 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Glenzocimab for Patients with Large Ischemic Stroke Eligible for Endovascular Therapy

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Acute Ischemic Stroke: A sudden interruption of blood flow to part of the brain, causing a lack of oxygen to brain tissue. This can lead to brain damage and is a medical emergency requiring prompt treatment.
  • Thrombolysis: A treatment for ischemic stroke that involves administering drugs to break down blood clots. It is typically given intravenously within 4.5 hours of stroke symptom onset.
  • Thrombectomy: A surgical procedure to remove a blood clot from a blood vessel. In stroke treatment, it refers to the mechanical removal of a clot from a brain artery.
  • Endovascular Therapy (EVT): A minimally invasive procedure used to treat problems affecting blood vessels, often from inside the blood vessel. In stroke treatment, it typically refers to mechanical thrombectomy.
  • Modified Rankin Scale (mRS): A scale used to measure the degree of disability in patients who have had a stroke. It ranges from 0 (no symptoms) to 6 (death).
  • National Institutes of Health Stroke Scale (NIHSS): A tool used to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between 0 and 4. A higher score indicates a more severe stroke.
  • Intracranial Hemorrhage (ICH): Bleeding within the skull, which can occur as a complication of stroke or its treatment. It can be symptomatic (causing noticeable symptoms) or asymptomatic.
  • Glycoprotein VI (GPVI): A protein on the surface of platelets that plays a crucial role in their activation and in the formation of blood clots. It is the target of the drug glenzocimab.
  • Downstream Microvascular Thrombosis (DMT): The formation of small blood clots in the tiny blood vessels downstream from a larger blocked artery in the brain during a stroke. This can worsen brain damage even after the initial larger clot is removed or dissolved.
  • No-Reflow Phenomenon: A condition where blood flow is not restored to an area of the brain even after the main blockage in a larger artery has been removed. This can be due to damage or blockages in smaller blood vessels.

References

  1. https://clinicaltrials.gov/study/NCT06437431
  2. https://clinicaltrials.eu/trial/study-on-glenzocimab-for-patients-with-acute-ischemic-stroke-undergoing-mechanical-thrombectomy/
  3. https://clinicaltrials.gov/study/NCT04659109
  4. https://clinicaltrials.gov/study/NCT05070260